Welcome to our dedicated page for US news (Ticker: US), a resource for investors and traders seeking the latest updates and insights on US stock.
The news feed for the ticker US on Stock Titan aggregates recent press releases and announcements from CoinShares International Limited, which in its own communications describes itself as a global or European investment firm and asset manager specialising in digital assets. These items provide qualitative insight into how the company presents its strategy, operations and view of the crypto and digital asset markets.
Readers can find quarterly results updates in which CoinShares discusses the performance of its Asset Management, Capital Markets and Principal Investments activities. These releases describe factors such as management fees from digital asset exchange-traded products, income from staking and liquidity provisioning, and the impact of digital asset price movements on its business. They also outline developments like accounting policy changes for digital asset holdings and the use of Bitcoin as a treasury instrument.
The news stream also includes product and platform milestones. Examples in the company’s own releases include the growth of CoinShares Physical Bitcoin (BITC), which CoinShares says has become a leading Bitcoin physical ETP in Europe by assets under management, and the integration of U.S. products under the CoinShares-Valkyrie brand. Other items cover regulatory achievements, such as MiCA authorisation for CoinShares Asset Management in France and the combination of AIFM, MiFID and MiCA permissions.
In addition, CoinShares publishes research-driven news, including digital asset outlooks and survey findings on financial advisors and wealthy investors. These pieces explore themes like hybrid finance, regulatory shifts and the demand for digital asset expertise. Together, the US-symbol news page offers a centralised view of how CoinShares reports on its financial performance, product evolution, regulatory status and market research over time.
Summary not available.
Core Laboratories N.V. (NYSE: CLB) announced its Board of Directors approved a plan for Redomestication from the Netherlands to the United States, specifically Delaware. This move aims to enhance shareholder value by simplifying corporate structure, improving operational efficiency, and reducing administrative costs. Shareholders will receive one share of Common Stock of Core Lab Delaware for each Common Share owned before the Redomestication. The Company believes this will result in reduced regulatory requirements and a more efficient tax structure. Shareholder approval is required, expected in the second quarter of 2023.
STADA is launching Hukyndra®, a high-concentration, citrate-free biosimilar to adalimumab, in select European markets including France, Germany, Finland, and Sweden. This launch follows approval from the European Commission and represents the first product from STADA's partnership with Alvotech. Hukyndra® is designed to enhance patient comfort with reduced injection-site pain. The biosimilar is approved for treating various inflammatory conditions, supporting patient access to vital therapies in Europe.